Egetis: Patients on Emcitate associated with survival benefits - Redeye

Redeye is optimistic about today’s news from Egetis Therapeutics that patients on Emcitate are associated with survival benefits compared to patients not on treatment. According to the release, Emcitate patients are “associated with an approximately three times lower risk of mortality compared to MCT8 deficiency patients not treated with tiratricol”, which clearly indicates a clinical relevance to treat chronic thyrotoxicosis in all patients. We will discuss these results more in relation to the Q2 report tomorrow.

Länk till analysen i sin helhet: https://www.redeye.se/research/1032010/egetis-patients-on-emcitate-associated-with-survival-benefits?utm_source=finwire&utm_medium=RSS